IRVINE, Calif., March 3, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, today announced that it will be supporting the cryogenic logistics requirements of ImmunoCellular Therapeutics' (NYSE MKT: IMUC) ("ImmunoCellular") registrational Phase III glioblastoma clinical trial across 120 sites in North America and Europe. This clinical trial is designed to evaluate the safety and efficacy of ImmunoCellular's lead product candidate ICT-107, a patient-derived dendritic cell-based immunotherapy.
Anthony Gringeri, ImmunoCellular's Senior Vice President, Strategic Resources, commented, "We chose to partner with Cryoport for the registrational trial of ICT-107 because of their cold chain logistics expertise and proven ability to manage the challenges of transporting valuable, temperature-sensitive cryogenically frozen materials. Of additional significance is their specialized logistics operating platform for the timely and secure delivery of our immunotherapy to the large number of patients participating in our trial in the US, Canada and Europe."
ImmunoCellular's ICT-107 immunotherapy targets six different antigens, peptides that are tumor markers, associated with the aggressive cancer of the brain, glioblastoma. More than 400 patients with newly diagnosed glioblastoma will be enrolled across 120 sites to participate in the trial. The regimen in the Phase III trial is standard of care plus or minus ICT-107 immunotherapy. The regimen includes induction immunotherapy (4 doses in month 1) and maintenance (monthly doses through month 12 or progression).
Jerrell Shelton, Chief Executive Officer of Cryoport, Inc. commented, "Our agreement with ImmunoCellular Therapeutics marks a substantial milestone in Cryoport's history as it is one of the largest volume trials we have supported. We are delighted that our advanced cryogenic logistics solutions will play an integral role in the execution of this Phase III trial. We will ensure the successful delivery of ImmunoCellular's immune-based therapy to the 120 sites located in North America and Europe as we employ our technology based solutions. With this partnership, Cryoport now supports 64 clinical trials worldwide, ten of which are Phase III trials."
"The biotech industry continues to develop advanced biologic and immunotherapeutic solutions that are sensitive to their environment and require the maintaining of specific temperatures during storage and transit. As these therapies have moved from the development stage and into the clinic, the need for a safe, effective and consistent way to transport them has become clearer to everyone in the industry. We are confident that our track record makes Cryoport an indispensable resource for the advancement of the biologics market," concluded Mr. Shelton.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.